Y-mAbs Therapeutics (YMAB) announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. Dr. LaFrance previously served as the Chief Medical Officer, Senior Vice President of PLUS Therapeutics (PSTV).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
- Y-mAbs Therapeutics announces publication of preclinical GD2-SADA data at ASCO
- Y-mAbs Therapeutics announces interim analysis of Phase 2 data for Naxitamab
- Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
- Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting